Low-dose Interleukin-8 Induces the Adhesion, Migration and Invasion of the Gastric Cancer SGC-7901 Cell Line

Overview

Journal Oncol Lett

Specialty Oncology

Date 2016 Jan 2

PMID 26722255

Citations 4

Authors

Jun Shi

Pin-Kang Wei

Affiliations

Soon will be listed here.

Abstract

Interleukin-8 (IL-8), an important inflammatory cytokine, is strongly associated with gastric cancer development and metastasis. High-dose (>1 ng/ml) IL-8 has been revealed to promote the adhesion, migration and invasion of human gastric cancer SGC-7901 cells in a dose-dependent manner. However, the IL-8 level produced by gastric cells is marginal, at even less than 1 ng/ml. It is unclear whether low-dose IL-8 also induces these capacities. In the present study, the effect of low-dose IL-8 on the adhesion, migration and invasion of the SGC-7901 cell line and the underlying molecular mechanism with regard to cluster of differentiation 44 (CD44) were investigated. The SGC-7901 cells were exposed to various concentrations of IL-8 (0, 0.2, 0.5, 0.8 and 1 ng/ml) . The adhesion of the SGC-7901 cells to fibronectin, an extracellular matrix component, was then detected by cell counting kit 8 assay. Migration and invasion abilities were evaluated by wound scratch and Transwell chamber assays. In addition, protein and mRNA levels of CD44 were measured using immunofluorescence and western blotting, and quantitative polymerase chain reaction, respectively, in cells cultured for 72 h. Following the exposure of the SGC-7901 cells to the various low doses of IL-8, the cell adhesion, migration and invasion capacities were promoted by IL-8, but not in a significant dose-dependent manner. Low-dose IL-8 upregulated the protein and mRNA expression of CD44. In conclusion, low-dose IL-8 potently induces the adhesion, migration and invasion of SGC-7901 cells, and the regulation of CD44 expression is one of the potential molecular mechanisms involved.

Citing Articles

Infiltration of T cells promotes the metastasis of ovarian cancer cells via the modulation of metastasis-related genes and PD-L1 expression.

Wang J, Siu M, Jiang Y, Chan D, Cheung A, Ngan H Cancer Immunol Immunother. 2020; 69(11):2275-2289.

PMID: 32504248 PMC: 11027631. DOI: 10.1007/s00262-020-02621-9.

CRISPR knockout screening identifies combinatorial drug targets in pancreatic cancer and models cellular drug response.

Szlachta K, Kuscu C, Tufan T, Adair S, Shang S, Michaels A Nat Commun. 2018; 9(1):4275.

PMID: 30323222 PMC: 6189038. DOI: 10.1038/s41467-018-06676-2.

CXCL8 derived from tumor-associated macrophages and esophageal squamous cell carcinomas contributes to tumor progression by promoting migration and invasion of cancer cells.

Hosono M, Koma Y, Takase N, Urakawa N, Higashino N, Suemune K Oncotarget. 2017; 8(62):106071-106088.

PMID: 29285315 PMC: 5739702. DOI: 10.18632/oncotarget.22526.

Effect of targeted silencing of IL-8 on migration and invasion of SKOV3 ovarian cancer cells.

Li Y, Liu L, Yin Z, Xu H, Li S, Tao W Oncol Lett. 2017; 13(2):567-572.

PMID: 28356930 PMC: 5351404. DOI: 10.3892/ol.2016.5511.

References

Kuai W, Wang Q, Yang X, Zhao Y, Yu R, Tang X . Interleukin-8 associates with adhesion, migration, invasion and chemosensitivity of human gastric cancer cells. World J Gastroenterol. 2012; 18(9):979-85. PMC: 3297059. DOI: 10.3748/wjg.v18.i9.979. View

Ju D, Sun D, Xiu L, Meng X, Zhang C, Wei P . Interleukin-8 is associated with adhesion, migration and invasion in human gastric cancer SCG-7901 cells. Med Oncol. 2010; 29(1):91-9. DOI: 10.1007/s12032-010-9780-0. View

Xie K . Interleukin-8 and human cancer biology. Cytokine Growth Factor Rev. 2001; 12(4):375-91. DOI: 10.1016/s1359-6101(01)00016-8. View

Jothy S . CD44 and its partners in metastasis. Clin Exp Metastasis. 2003; 20(3):195-201. DOI: 10.1023/a:1022931016285. View

Kitadai Y, Takahashi Y, Haruma K, Naka K, Sumii K, Yokozaki H . Transfection of interleukin-8 increases angiogenesis and tumorigenesis of human gastric carcinoma cells in nude mice. Br J Cancer. 1999; 81(4):647-53. PMC: 2362886. DOI: 10.1038/sj.bjc.6690742. View

Martin T, Mason M, Jiang W . Tight junctions in cancer metastasis. Front Biosci (Landmark Ed). 2011; 16(3):898-936. DOI: 10.2741/3726. View

Matsuo Y, Ochi N, Sawai H, Yasuda A, Takahashi H, Funahashi H . CXCL8/IL-8 and CXCL12/SDF-1alpha co-operatively promote invasiveness and angiogenesis in pancreatic cancer. Int J Cancer. 2008; 124(4):853-61. PMC: 2684108. DOI: 10.1002/ijc.24040. View

Wang D, Chen G, Liu X, Miao Y, Xia J, Zhu L . CD44v6 in peripheral blood and bone marrow of patients with gastric cancer as micro-metastasis. World J Gastroenterol. 2006; 12(1):36-42. PMC: 4077475. DOI: 10.3748/wjg.v12.i1.36. View

Christofakis E, Miyazaki H, Rubink D, Yeudall W . Roles of CXCL8 in squamous cell carcinoma proliferation and migration. Oral Oncol. 2008; 44(10):920-6. DOI: 10.1016/j.oraloncology.2007.12.002. View

10.

Kitadai Y, Haruma K, Sumii K, Yamamoto S, Ue T, Yokozaki H . Expression of interleukin-8 correlates with vascularity in human gastric carcinomas. Am J Pathol. 1998; 152(1):93-100. PMC: 1858127. View

11.

Kamohara H, Takahashi M, Ishiko T, Ogawa M, Baba H . Induction of interleukin-8 (CXCL-8) by tumor necrosis factor-alpha and leukemia inhibitory factor in pancreatic carcinoma cells: Impact of CXCL-8 as an autocrine growth factor. Int J Oncol. 2007; 31(3):627-32. View

12.

Kido S, Kitadai Y, Hattori N, Haruma K, Kido T, Ohta M . Interleukin 8 and vascular endothelial growth factor -- prognostic factors in human gastric carcinomas?. Eur J Cancer. 2001; 37(12):1482-7. DOI: 10.1016/s0959-8049(01)00147-2. View

13.

Campbell L, Maxwell P, Waugh D . Rationale and Means to Target Pro-Inflammatory Interleukin-8 (CXCL8) Signaling in Cancer. Pharmaceuticals (Basel). 2013; 6(8):929-59. PMC: 3817732. DOI: 10.3390/ph6080929. View

14.

Ghaffarzadehgan K, Jafarzadeh M, Raziee H, Sima H, Esmaili-Shandiz E, Hosseinnezhad H . Expression of cell adhesion molecule CD44 in gastric adenocarcinoma and its prognostic importance. World J Gastroenterol. 2008; 14(41):6376-81. PMC: 2766121. DOI: 10.3748/wjg.14.6376. View

15.

Parkin D, Bray F, Ferlay J, Pisani P . Global cancer statistics, 2002. CA Cancer J Clin. 2005; 55(2):74-108. DOI: 10.3322/canjclin.55.2.74. View

16.

Iwai M, Matsuda M, Iwai Y . Cloning of a cancer cell-producing hepatocyte growth factor, vascular endothelial growth factor, and interleukin-8 from gastric cancer cells. In Vitro Cell Dev Biol Anim. 2003; 39(7):288-90. DOI: 10.1290/1543-706X(2003)039<0288:COACCH>2.0.CO;2. View

17.

Waugh D, Wilson C . The interleukin-8 pathway in cancer. Clin Cancer Res. 2008; 14(21):6735-41. DOI: 10.1158/1078-0432.CCR-07-4843. View

18.

Itoh Y, Joh T, Tanida S, Sasaki M, Kataoka H, Itoh K . IL-8 promotes cell proliferation and migration through metalloproteinase-cleavage proHB-EGF in human colon carcinoma cells. Cytokine. 2005; 29(6):275-82. DOI: 10.1016/j.cyto.2004.11.005. View

19.

Zhu Y, Woll P . Mitogenic effects of interleukin-8/CXCL8 on cancer cells. Future Oncol. 2006; 1(5):699-704. DOI: 10.2217/14796694.1.5.699. View

20.

Baggiolini M, Clark-Lewis I . Interleukin-8, a chemotactic and inflammatory cytokine. FEBS Lett. 1992; 307(1):97-101. DOI: 10.1016/0014-5793(92)80909-z. View